La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Imagion Biosystems Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	7.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Feb 28

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Jan 06

AMMINISTRATORE DELEGATO

Imagion Biosystems non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Proulx	Executive Chairman	9.5yrs	AU$409.30k	0.44% A$ 6.0k
Ward Detwiller	Chief Business Officer	less than a year	Nessun dato	Nessun dato
Melanie Leydin	Company Secretary	less than a year	Nessun dato	Nessun dato

0.6yrs

Durata media

Gestione esperta: Il team dirigenziale di IBX non è considerato esperto (durata media 0.6 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Proulx	Executive Chairman	9.5yrs	AU$409.30k	0.44% A$ 6.0k
David Ludvigson	Non Executive Director	7.4yrs	AU$46.56k	0.039% A$ 531.3
Brett Mitchell	Non-Executive Director	less than a year	Nessun dato	1.49% A$ 20.3k
Michael Harsh	Non-Executive Director	7.5yrs	AU$46.56k	0.019% A$ 253.5
Mark Van Asten	Non Executive Director	7.7yrs	AU$41.35k	0.044% A$ 597.8

7.5yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IBX sono considerati esperti (durata media dell'incarico 7.5 anni).

Imagion Biosystems Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Imagion Biosystems Limited Announces Board Changes

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

Recent updates

New minor risk - Shareholder dilution

Imagion Biosystems Limited Announces Board Changes

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.35 loss in FY 2022)

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

New major risk - Market cap size

First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2022)

New major risk - Financial position

New minor risk - Financial data availability

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

New minor risk - Share price stability

Imagion Biosystems Limited Announces CEO Changes

New major risk - Market cap size

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Reports Positive Clinical Data At Breast Cancer Symposium

No independent directors

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

First half 2022 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2021)

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 25, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Imagion Biosystems Limited Announces First Patient Enrolled in the MagSense® HER2 Breast Cancer Phase I First-In-Human Study

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Imagion Biosystems Limited Receives CSIRO Grant for Prostate Cancer Project

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Full year 2020 earnings released: AU$0.007 loss per share (vs AU$0.01 loss in FY 2019)

New 90-day high: AU$0.21

New 90-day high: AU$0.21

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Provides First-In-Human Study Update - Study Open for Enrolment

Imagion Biosystems Limited Announces Change of Company Secretary

Imagion Biosystems Limited announced that it expects to receive AUD 6 million in funding

Imagion Biosystems Limited Appoints Geoff Hollis as CFO

Imagion Biosystems Announces HREC Approval for Phase I Study

First half earnings released

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media